Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00006435
Other study ID # 010027
Secondary ID 01-C-0027
Status Completed
Phase
First received
Last updated
Start date May 18, 2001
Est. completion date May 1, 2020

Study information

Verified date May 2020
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

-Plexiform neurofibromas in patients with NF1 are a significant cause of morbidity but little is known about the natural history of these lesions.

Objectives:

- The purpose of this study is to monitor the natural history of plexiform neurofibromas and to evaluate the usefulness of volumetric MRI tumor measurements in this disease.

- Other goals of the study are to provide a body of normative data on the growth rate of plexiform neurofibromas and to establish a tissue repository and pathology review center to allow future studies of the pathogenesis of neurofibromas and clinical trials of potential therapeutic agents.

Design

- This study is coordinated by Dr. Bruce Korf, and was initiated when he was at the Partners Center for Human Genetics, Boston, MA.


Description:

Background:

-Plexiform neurofibromas in patients with NF1 are a significant cause of morbidity but little is known about the natural history of these lesions.

Objectives:

- The purpose of this study is to monitor the natural history of plexiform neurofibromas and to evaluate the usefulness of volumetric MRI tumor measurements in this disease.

- Other goals of the study are to provide a body of normative data on the growth rate of plexiform neurofibromas and to establish a tissue repository and pathology review center to allow future studies of the pathogenesis of neurofibromas and clinical trials of potential therapeutic agents.

Design

- This study is coordinated by Dr. Bruce Korf, and was initiated when he was at the Partners Center for Human Genetics, Boston, MA.


Other known NCT identifiers
  • NCT00445991

Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date May 1, 2020
Est. primary completion date September 7, 2007
Accepts healthy volunteers No
Gender All
Age group N/A to 100 Years
Eligibility - INCLUSION

- Diagnosis of Neurofibromatosis: All study subjects will fulfill two or more of the diagnostic criteria listed below for NF1.

- Six or more caf(SqrRoot)(Copyright)-au-lait macules

- 1.5cm or larger in postpubertal individuals

- 0.5 cm or larger in prepubertal individuals

- Two or more neurofibromas of any type or 1 or more plexiform neurofibroma

- Freckling in the axilla or groin

- Optic glioma (tumor of the optic pathway)

- Two or more Lisch nodules (benign iris hamartomas)

- A distinctive bony lesion

- Dysplasia of the sphenoid bone

- Dysplasia or thinning of long bone cortex

- A first degree relative with NF-1

- Plexiform Neurofibroma: A plexiform neurofibroma fulfilling entry criteria for the study will be defined as a diffuse soft tissue or nerve enlargement in a patient with NF1 that is causing, or has potential to cause, disfigurement or functional disability.

- Distribution of Plexiform Neurofibromas by site: A total of 300 plexiform neurofibromas will be studied, consisting of 100 tumors in the following three groups (based on region of maximal involvement):

- Head and Neck

- Trunk and Limbs (externally visible)

- Trunk and Limbs (internal) [spinal plexiform neurofibromas involve two or more levels with connection between the levels or extending laterally along the nerve]

- Subject Ascertainment: Study subjects will be ascertained at any of the participating clinical centers. It is expected that these will include subjects already followed in these clinics, as well as newly diagnosed patients

EXCLUSION

- Presence of metallic implant(s) that will make the patient unable to have MRI studies

- Presence of medical or psychological condition that will make the patient unable to tolerate MRI studies or anesthesia (if needed)

- Inability to image tumor or define tumor margins by MRI (which may be determined after the initial study)

- Failure to obtain initial MRI within 60 days of enrollment

- Previous radiation therapy to site of plexiform neurofibroma

- Surgery involving the plexiform neurofibroma (excluding biopsy) within a six month period before enrollment

- Current antineoplastic therapy

- Entry of more than one member of the same family into the study is not permitted

Study Design


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Monitor natural history of plexiform neurofibromas Monitor natural history of plexiform neurofibromas 3 years
Primary Usefulness of volumetric MRI measurements Usefulness of volumetric MRI measurements 4 years
Secondary Establish tissue repository & pathology reviews center 3 years
Secondary Body of data regarding growth rate of plexiform neurofibromas 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01362803 - AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Phase 1/Phase 2
Recruiting NCT06104488 - A Study of Avutometinib for People With Solid Tumor Cancers Phase 1
Recruiting NCT02964884 - Interventions for Reading Disabilities in NF1 Phase 2
Completed NCT00684398 - Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I
Recruiting NCT05238909 - Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1
Active, not recruiting NCT04954001 - Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 Phase 1/Phase 2
Terminated NCT01402817 - Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Phase 2
Terminated NCT02718131 - A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1) N/A
Completed NCT02101736 - Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Phase 2
Recruiting NCT05913037 - FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas Phase 3
Completed NCT01275586 - Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Early Phase 1
Recruiting NCT06159166 - Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). Phase 1/Phase 2
Not yet recruiting NCT05253131 - Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Phase 2
Recruiting NCT04544007 - A Phase II Trial of Poly-ICLC for Low-Grade Gliomas Phase 2